The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle
Open accessAbstract
Potent sequence selective gene inhibition by siRNA 'targeted' therapeutics promises the ultimate level of specificity, but siRNA therapeutics is hindered by poor intracellular uptake, limited blood stability and non-specific immune stimulation. To address these problems, ligand-targeted, sterically stabilized nanoparticles have been adapted for siRNA. Self-assembling nanoparticles with siRNA were constructed with polyethyleneimine (PEI) that is PEGylated with an Arg-Gly-Asp (RGD) peptide ligand attached at the distal end of the polyethylene glycol (PEG), as a means to target tumor neovasculature expressing integrins and used to deliver siRNA inhibiting vascular endothelial growth factor receptor-2 (VEGF R2) expression and thereby tumor angiogenesis. Cell delivery and activity of PEGylated PEI was found to be siRNA sequence specific and depend on the presence of peptide ligand and could be competed by free peptide. Intravenous administration into tumor-bearing mice gave selective tumor uptake, siRNA sequence-specific inhibition of protein expression within the tumor and inhibition of both tumor angiogenesis and growth rate. The results suggest achievement of two levels of targeting: tumor tissue selective delivery via the nanoparticle ligand and gene pathway selectivity via the siRNA oligonucleotide. This opens the door for better targeted therapeutics with both tissue and gene selectivity, also to improve targeted therapies with less than ideal therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
TOLENTINO, M. J., BRUCKER, A. J., FOSNOT, J., YING, G.-S., WU, I.-H., MALIK, G., WAN, S., & REICH, S. J. (2004) · RETINA · doi:10.1097/00006982-200402000-00018 · Cited by 172
RetractedRGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 3×
“Even the emergence of ‘targeted’ cancer therapeutics inhibiting tumor-specific proteins or pathways, such as anti-vascular endothelial growth factor (VEGF) antibody (1), has not eliminated problems of toxicity.”
BackgroundMethodCpG Motifs in Bacterial DNA and Their Immune Effects
Krieg, A. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064842 · Cited by 2,573
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Organ targeting In vivo using phage display peptide libraries
Pasqualini, R., & Ruoslahti, E. (1996) · Nature · doi:10.1038/380364a0 · Cited by 1,221
RNA interference targeting Fas protects mice from fulminant hepatitis
Song, E., Lee, S.-K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., & Lieberman, J. (2003) · Nature Medicine · doi:10.1038/nm828 · Cited by 1,110
Analysis of gene function in somatic mammalian cells using small interfering RNAs
Elbashir, S. (2002) · Methods · doi:10.1016/s1046-2023(02)00023-3 · Cited by 1,095
Tumor Regression by Targeted Gene Delivery to the Neovasculature
Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., & Cheresh, D. A. (2002) · Science · doi:10.1126/science.1070200 · Cited by 858
In vivo activity of nuclease-resistant siRNAs
LAYZER, J. M., MCCAFFREY, A. P., TANNER, A. K., HUANG, Z., KAY, M. A., & SULLENGER, B. A. (2004) · RNA · doi:10.1261/rna.5239604 · Cited by 580
Cited by
Nanocarriers’ entry into the cell: relevance to drug delivery
Hillaireau, H., & Couvreur, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0053-z · Cited by 1,552
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
Polymer Therapeutics: Concepts and Applications
Haag, R., & Kratz, F. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502113 · Cited by 1,115
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Therapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis
Danhier, F., Le Breton, A., & Préat, V. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3002733 · Cited by 955
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 878
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Delivery of siRNA Therapeutics: Barriers and Carriers
Wang, J., Lu, Z., Wientjes, M. G., & Au, J. L.-S. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9210-4 · Cited by 798
Progress in developing cationic vectors for non-viral systemic gene therapy against cancer
Morille, M., Passirani, C., Vonarbourg, A., Clavreul, A., & Benoit, J.-P. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.04.036 · Cited by 769
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Role of nanotechnology in targeted drug delivery and imaging: a concise review
Koo, O. M., Rubinstein, I., & Onyuksel, H. (2005) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2005.06.004 · Cited by 718
Farazi, T. A., Hoell, J. I., Morozov, P., & Tuschl, T. (2013) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-007-5590-1_1 · Cited by 693
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
Rozema, D. B., Lewis, D. L., Wakefield, D. H., Wong, S. C., Klein, J. J., Roesch, P. L., Bertin, S. L., Reppen, T. W., Chu, Q., Blokhin, A. V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703778104 · Cited by 658
Hatakeyama, H., Akita, H., & Harashima, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.001 · Cited by 645
Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery
van Vlerken, L. E., Vyas, T. K., & Amiji, M. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9284-6 · Cited by 645
Nanotechnology for the biologist
McNeil, S. E. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0205074 · Cited by 613
Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond)
Lächelt, U., & Wagner, E. (2015) · Chemical Reviews · doi:10.1021/cr5006793 · Cited by 600
RNA Interference in Vitro and in Vivo Using a Novel Chitosan/siRNA Nanoparticle System
Howard, K. A., Rahbek, U. L., Liu, X., Damgaard, C. K., Glud, S. Z., Andersen, M. Ø., Hovgaard, M. B., Schmitz, A., Nyengaard, J. R., Besenbacher, F., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.04.010 · Cited by 585
Recent Advances in Nonviral Vectors for Gene Delivery
Guo, X., & Huang, L. (2012) · Accounts of Chemical Research · doi:10.1021/ar200151m · Cited by 584
Lanthanides in magnetic resonance imaging
Bottrill, M., Kwok, L., & Long, N. J. (2006) · Chemical Society Reviews · doi:10.1039/b516376p · Cited by 583
Nucleic Acid Based Molecular Devices
Krishnan, Y., & Simmel, F. C. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.200907223 · Cited by 572
Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 567
Oligonucleotide Loading Determines Cellular Uptake of DNA-Modified Gold Nanoparticles
Giljohann, D. A., Seferos, D. S., Patel, P. C., Millstone, J. E., Rosi, N. L., & Mirkin, C. A. (2007) · Nano Letters · doi:10.1021/nl072471q · Cited by 552
Molecular Imaging with Theranostic Nanoparticles
Jokerst, J. V., & Gambhir, S. S. (2011) · Accounts of Chemical Research · doi:10.1021/ar200106e · Cited by 548
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
Tumour-targeted nanomedicines: principles and practice
Lammers, T., Hennink, W. E., & Storm, G. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604483 · Cited by 542
Oh, E. J., Park, K., Kim, K. S., Kim, J., Yang, J.-A., Kong, J.-H., Lee, M. Y., Hoffman, A. S., & Hahn, S. K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.010 · Cited by 540
Nanoparticles in Biological Systems
Stark, W. J. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.200906684 · Cited by 535
Nanoparticles and targeted drug delivery in cancer therapy
Bahrami, B., Hojjat-Farsangi, M., Mohammadi, H., Anvari, E., Ghalamfarsa, G., Yousefi, M., & Jadidi-Niaragh, F. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.07.015 · Cited by 510
Hatakeyama, H., Akita, H., & Harashima, H. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00059 · Cited by 495
Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target
Peer, D., Park, E. J., Morishita, Y., Carman, C. V., & Shimaoka, M. (2008) · Science · doi:10.1126/science.1149859 · Cited by 493
Quantum Dots with a Paramagnetic Coating as a Bimodal Molecular Imaging Probe
Mulder, W. J. M., Koole, R., Brandwijk, R. J., Storm, G., Chin, P. T. K., Strijkers, G. J., de Mello Donegá, C., Nicolay, K., & Griffioen, A. W. (2006) · Nano Letters · doi:10.1021/nl051935m · Cited by 482
Simple Modifications of Branched PEI Lead to Highly Efficient siRNA Carriers with Low Toxicity
Zintchenko, A., Philipp, A., Dehshahri, A., & Wagner, E. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800065f · Cited by 467
Temming, K., Schiffelers, R. M., Molema, G., & Kok, R. J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.10.002 · Cited by 467
Self-citationNonviral delivery of synthetic siRNAs in vivo
Akhtar, S., & Benter, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33494 · Cited by 464
Aptamer mediated siRNA delivery
Chu, T. C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl388 · Cited by 446
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
Juliano, R., Alam, M. R., Dixit, V., & Kang, H. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn342 · Cited by 429
Nanotechnology, nanotoxicology, and neuroscience
Suh, W. H., Suslick, K. S., Stucky, G. D., & Suh, Y.-H. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.09.009 · Cited by 406
Hatakeyama, H., Akita, H., Kogure, K., Oishi, M., Nagasaki, Y., Kihira, Y., Ueno, M., Kobayashi, H., Kikuchi, H., & Harashima, H. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302843 · Cited by 398
Targeted Quantum Dot Conjugates for siRNA Delivery
Derfus, A. M., Chen, A. A., Min, D.-H., Ruoslahti, E., & Bhatia, S. N. (2007) · Bioconjugate Chemistry · doi:10.1021/bc060367e · Cited by 395
Gene therapy progress and prospects: non-viral gene therapy by systemic delivery
Li, S.-D., & Huang, L. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302838 · Cited by 391
The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing
Liu, X., Howard, K. A., Dong, M., Andersen, M. Ø., Rahbek, U. L., Johnsen, M. G., Hansen, O. C., Besenbacher, F., & Kjems, J. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.11.004 · Cited by 391
RNA interference: From gene silencing to gene-specific therapeutics
Leung, R. K. M., & Whittaker, P. A. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.03.004 · Cited by 382
Nonviral cancer gene therapy: Delivery cascade and vector nanoproperty integration
Zhou, Z., Liu, X., Zhu, D., Wang, Y., Zhang, Z., Zhou, X., Qiu, N., Chen, X., & Shen, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.021 · Cited by 379
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium
Santel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V, Fisch, G., Dames, S., Löffler, K., Fechtner, M., Arnold, W., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302777 · Cited by 368
Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer
Kawasaki, E. S., & Player, A. (2005) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2005.03.002 · Cited by 368
Polymeric Delivery of Therapeutic Nucleic Acids
Kumar, R., Santa Chalarca, C. F., Bockman, M. R., Bruggen, C. V., Grimme, C. J., Dalal, R. J., Hanson, M. G., Hexum, J. K., & Reineke, T. M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00997 · Cited by 365
Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels
Lee, H., Mok, H., Lee, S., Oh, Y.-K., & Park, T. G. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.02.011 · Cited by 365
Zhang, R., Qin, X., Kong, F., Chen, P., & Pan, G. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1582730 · Cited by 363
Kim, S. H., Jeong, J. H., Lee, S. H., Kim, S. W., & Park, T. G. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.03.008 · Cited by 362
Prospects of RNA interference therapy for cancer
Pai, S. I., Lin, Y.-Y., Macaes, B., Meneshian, A., Hung, C.-F., & Wu, T.-C. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302694 · Cited by 352
Artificial viruses: a nanotechnological approach to gene delivery
Mastrobattista, E., van der Aa, M. A. E. M., Hennink, W. E., & Crommelin, D. J. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1960 · Cited by 346
Polyethylenimine (PEI) in gene therapy: Current status and clinical applications
Casper, J., Schenk, S. H., Parhizkar, E., Detampel, P., Dehshahri, A., & Huwyler, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.001 · Cited by 340
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 336
Tumor-targeted Delivery of siRNA by Self-assembled Nanoparticles
Li, S.-D., Chen, Y.-C., Hackett, M. J., & Huang, L. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300323 · Cited by 333
Matsumoto, S., Christie, R. J., Nishiyama, N., Miyata, K., Ishii, A., Oba, M., Koyama, H., Yamasaki, Y., & Kataoka, K. (2009) · Biomacromolecules · doi:10.1021/bm800985e · Cited by 327
Nanoparticles: Functionalization and Multifunctional Applications in Biomedical Sciences
Subbiah, R., Veerapandian, M., & S. Yun, K. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710794183024 · Cited by 327
Biophysical and Structural Characterization of Polyethylenimine-Mediated siRNA Delivery in Vitro
Richards Grayson, A. C., Doody, A. M., & Putnam, D. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9009-2 · Cited by 324
The silent treatment: siRNAs as small molecule drugs
Dykxhoorn, D. M., Palliser, D., & Lieberman, J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302703 · Cited by 324
Integrin αvβ3‐targeted cancer therapy
Liu, Z., Wang, F., & Chen, X. (2008) · Drug Development Research · doi:10.1002/ddr.20265 · Cited by 323
Joralemon, M. J., O'Reilly, R. K., Hawker, C. J., & Wooley, K. L. (2005) · Journal of the American Chemical Society · doi:10.1021/ja053919x · Cited by 319
Mao, S., Neu, M., Germershaus, O., Merkel, O., Sitterberg, J., Bakowsky, U., & Kissel, T. (2006) · Bioconjugate Chemistry · doi:10.1021/bc060129j · Cited by 319
Sustained Small Interfering RNA Delivery by Mesoporous Silicon Particles
Tanaka, T., Mangala, L. S., Vivas-Mejia, P. E., Nieves-Alicea, R., Mann, A. P., Mora, E., Han, H.-D., Shahzad, M. M. K., Liu, X., Bhavane, R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3931 · Cited by 316
v Integrins in Angiogenesis and Cancer
Weis, S. M., & Cheresh, D. A. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006478 · Cited by 311
Efficient and targeted delivery of siRNA in vivo
Shim, M. S., & Kwon, Y. J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07904.x · Cited by 309
Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 Therapy
Zhou, J., Li, H., Li, S., Zaia, J., & Rossi, J. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.92 · Cited by 301
Engineering RNA for Targeted siRNA Delivery and Medical Application
Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 300
van Dijk, M., Rijkers, D. T. S., Liskamp, R. M. J., van Nostrum, C. F., & Hennink, W. E. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900087a · Cited by 300
Aleku, M., Schulz, P., Keil, O., Santel, A., Schaeper, U., Dieckhoff, B., Janke, O., Endruschat, J., Durieux, B., Röder, N., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2428 · Cited by 293
Overcoming the Innate Immune Response to Small Interfering RNA
Judge, A., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.179 · Cited by 284
Nanoparticle‐Mediated Drug Delivery and Gene Therapy
Jin, S., & Ye, K. (2007) · Biotechnology Progress · doi:10.1021/bp060348j · Cited by 283
Li, S.-D., & Huang, L. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060039w · Cited by 282
PEG conjugated VEGF siRNA for anti-angiogenic gene therapy
Kim, S. H., Jeong, J. H., Lee, S. H., Kim, S. W., & Park, T. G. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.023 · Cited by 273
Reissmann, S. (2014) · Journal of Peptide Science · doi:10.1002/psc.2672 · Cited by 266
Jain, K. K. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6966-1 · Cited by 264
Molecular imaging with nanoparticles: giant roles for dwarf actors
Debbage, P., & Jaschke, W. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0511-y · Cited by 264
Prakash, S., Malhotra, M., Shao, W., Tomaro-Duchesneau, C., & Abbasi, S. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.013 · Cited by 256
Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020) · Advanced Materials · doi:10.1002/adma.201901081 · Cited by 255
Drug delivery of siRNA therapeutics: potentials and limits of nanosystems
Reischl, D., & Zimmer, A. (2009) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2008.06.001 · Cited by 253
Biodegradable, polymeric nanoparticle delivery systems for cancer therapy
Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2007) · Nanomedicine · doi:10.2217/17435889.2.5.669 · Cited by 249
Nonviral methods for siRNA delivery
Gao, K., & Huang, L. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800134q · Cited by 244
Osada, K., Christie, R. J., & Kataoka, K. (2009) · Journal of The Royal Society Interface · doi:10.1098/rsif.2008.0547.focus · Cited by 218
Lipid nanoparticles for short interfering RNA delivery
Leung, A. K. K., Tam, Y. Y. C., & Cullis, P. R. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00004-3 · Cited by 158
Geekiyanage, H., Rayatpisheh, S., Wohlschlegel, J. A., Brown, R., & Ambros, V. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008323117 · Cited by 148
RGD peptide-based non-viral gene delivery vectors targeting integrin α v β 3 for cancer therapy
Fu, S., Xu, X., Ma, Y., Zhang, S., & Zhang, S. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2018.1455841 · Cited by 139
Targeted Delivery of Small Interfering RNA: Approaching Effective Cancer Therapies
Pirollo, K. F., & Chang, E. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5810 · Cited by 121
“(9) linked siRNA against vascular endothelial growth factor (VEGF) receptor 2 to polyethyleneimine that was PEGylated with an RGD peptide ligand at the distal end as a means to target tumor neovasculature.”
MethodTargeted Drug Delivery via the Use of ECM-Mimetic Materials
Hwang, J., Sullivan, M. O., & Kiick, K. L. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00069 · Cited by 76
Takahashi, H., Wang, Y., & Grainger, D. W. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.019 · Cited by 58
Zhou, L., Chen, Z., Chi, W., Yang, X., Wang, W., & Zhang, B. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.11.060 · Cited by 54
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Metadata
- Authors
- Schiffelers, R. M.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-10-28
- Volume
- 32
- Issue
- 19
- Pages
- e149-e149
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2126630077
- Cited by
- 901
- References
- 35
- FWCI
- 20.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.